natgillin/translations-raw huggingface dataset:
There was no clinically relevant difference in pharmacokinetics of Levemir between patients with renal or hepatic impairment and healthy subjects.
Klinično pomembne razlike v farmakokinetiki zdravila Levemir med bolniki z ledvično ali jetrno okvaro in zdravimi ljudmi niso bile ugotovljene.
Mean HbA1c (%) at GW 36
Povprečni HbA1c (%) v 36.
Levemir was non-inferior to NPH insulin as measured by HbA1c at gestational week (GW) 36, and the reduction in mean HbA1c through pregnancy was similar, see table 4.
Zdravilo Levemir je bilo enakovredno insulinu NPH, merjeno s HbA1c v 36. tednu nosečnosti (TN), in znižanje povprečnega HbA1c med nosečnostjo je bilo podobno (glejte preglednico 4).
There are limited data in patients with severe hypoalbuminaemia.
Pri bolnikih s hudo hipoalbuminemijo ni zadosti podatkov.
Levemir is used to reduce the high blood sugar level in adults, adolescents and children aged 1 year and above with diabetes mellitus (diabetes).
Zdravilo Levemir se uporablja za znižanje visokega krvnega sladkorja pri odraslih, mladostnikih in otrocih, starih 1 leto in več, s sladkorno boleznijo.
► Levemir Penfill cartridges are designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist needles.
► Vložki Levemir Penfill so namenjeni za uporabo s sistemi za dajanje insulina Novo Nordisk in iglami NovoFine ali NovoTwist.
.0.4 U/kg
.0,4 e./kg
The prolonged action of Levemir is mediated by the strong self-association of insulin detemir molecules at the injection site and albumin binding via the fatty acid side-chain.
Na podaljšano delovanje zdravila Levemir vpliva močna medsebojna povezava molekul insulina detemir na mestu injiciranja in vezava na albumin preko stranskih verig maščobnih kislin.
Minor hypoglycaemic episodes (per patient year)
Blage hipoglikemije (na bolnik-leto)
As with any insulin therapy, injection site reactions may occur and include pain, redness, hives, inflammation, bruising, swelling and itching.
Kot pri vsakem zdravljenju z insulinom se lahko pojavijo reakcije na mestu injiciranja, vključno z bolečinami, pordelostjo, koprivnico, vnetjem, podplutbami, oteklino in srbenjem.
A 26-week, double blind, randomised clinical trial was conducted to investigate the efficacy and safety of adding liraglutide (1.8 mg) vs. placebo in patients with type 2 diabetes inadequately controlled on basal insulin with or without metformin.
V 26-tedenskem, dvojno slepem, randomiziranem kliničnem preskušanju so vrednotili učinkovitost in varnost liraglutida (1,8 mg) v primerjavi s placebom pri bolnikih s sladkorno boleznijo tipa 2 z nezadostno urejeno glikemijo pri zdravljenju z bazalnim insulinom, z metforminom ali brez njega.
If you forget to take your insulin your blood sugar may get too high (hyperglycaemia).
Če ste si pozabili injicirati vaš insulin, se vam lahko krvni sladkor preveč zviša (hiperglikemija).
Each ml contains 100 units of insulin detemir.
En ml vsebuje 100 enot insulina detemir.
When Levemir is used in combination with tablets for diabetes and/or in combination with injectable anti-diabetic products, other than insulin, Levemir should be administered once a day.
Če je zdravilo Levemir uporabljeno v kombinaciji s tabletami za zdravljenje sladkorne bolezni in/ali v kombinaciji z neinsulinskimi zdravili za zdravljenje sladkorne bolezni za injiciranje, je treba zdravilo Levemir uporabljati enkrat na dan.
The overall rates of maternal adverse events were similar for Levemir and NPH insulin treatment groups; however, a numerically higher frequency of serious adverse events in the mothers (61 (40%) vs. 49 (31%)) and in the newborn children (36 (24%) vs. 32 (20%)) was seen for Levemir compared to NPH insulin.
V celoti so bili deleži neželenih učinkov pri materah v terapevtski skupini z zdravilom Levemir in terapevtski skupini z insulinom NPH podobni, vendar so v skupini z zdravilom Levemir tako pri materah kot pri novorojenčkih zabeležili številčno večjo pogostnost resnih neželenih učinkov kot v skupini z insulinom NPH (zdravilo Levemir: matere 61 (40 %), novorojenčki 36 (24 %); insulin NPH: matere 49 (31 %), novorojenčki 32 (20 %)).
Rate Ratio:
Razmerje deležev:
OTHER SPECIAL WARNINGS, IF NECESSARY Use only solution if water clear, colourless and aqueous For use by one person only
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Raztopino uporabite le, če je povsem bistra, brezbarvna in vodna.
Other medicines and Levemir
Druga zdravila in zdravilo Levemir
• Replace the big outer needle cap and unscrew the needle (picture E).
• Veliki zunanji pokrovček igle namestite nazaj in iglo odvijte (slika E).
Analyses of nocturnal hypoglycaemia in patients with type 1 diabetes showed a significantly lower risk of minor nocturnal hypoglycaemia (able to self-treat and confirmed by capillary blood glucose less than 2.8 mmol/l or 3.1 mmol/l if expressed as plasma glucose) than with NPH insulin, whereas no difference was seen in type 2 diabetes.
Analize nočne hipoglikemije pri bolnikih s sladkorno boleznijo tipa 1 so pokazale bistveno nižje tveganje za blago nočno hipoglikemijo (kadar ni potrebno dodatno zdravljenje in je glukoza v kapilarni krvi nižja od 2,8 mmol/l ali 3,1 mmol/l, če je izražena kot plazemska glukoza) kot pri insulinu NPH, pri sladkorni bolezni tipa 2 pa ta razlika ni opazna.
When turning the dose selector be careful not to push the pushbutton as insulin will come out.
Med vrtenjem izbirnika odmerka pazite, da ne pritisnete na potisni gumb, ker bi s tem iztisnili insulin.
The blood glucose lowering effect of Levemir is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.
Zdravilo Levemir znižuje glukozo v krvi tako, da olajša njen privzem po vezavi insulina na receptorje na mišičnih in maščobnih celicah in hkrati zavre sproščanje glukoze iz jeter.
When a GLP-1 receptor agonist is added to Levemir, it is recommended to reduce the dose of Levemir by 20% to minimise the risk of hypoglycaemia.
Če se agonist receptorjev GLP-1 doda k zdravljenju z zdravilom Levemir, je odmerek zdravila Levemir priporočljivo zmanjšati za 20 %, da se zmanjša tveganje za hipoglikemijo, kasneje pa je odmerek treba prilagoditi pri vsakem bolniku posebej.
The insulin dose was reduced by 20% for patients with baseline HbA1c ≤8.0% in order to minimise the risk of hypoglycaemia.
Pri bolnikih z izhodiščno vrednostjo HbA1c ≤ 8,0 % so odmerek insulina zmanjšali za 20 % zaradi zmanjšanja tveganja za pojav hipoglikemije.
Can be stored in a refrigerator (2°C-8°C).
Shranjujete lahko tudi v hladilniku (2 °C - 8 °C).
B Remove the paper tab from a new disposable needle.
C. Odstranite papirno nalepko z nove igle za enkratno uporabo.
Before using Levemir
Preden uporabite zdravilo Levemir
Levemir is administered subcutaneously by injection in the abdominal wall, the thigh, the upper arm, the deltoid region or the gluteal region.
Zdravilo Levemir se aplicira subkutano z injekcijo v trebušno steno, stegno, nadlaket, deltoidni ali glutealni predel.
3 ml solution in cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene.
3 ml raztopine v vložku (steklo tipa I) z batom (brombutil) in gumijasto zaporko (brombutil/poliizopren), vstavljenim v napolnjen večodmeren injekcijski peresnik iz polipropilena, ki se ga zavrže, ko je izrabljen.
Caregivers must be very careful when handling used needles -to reduce the risk of needle sticks and cross-infection.
Osebe, ki skrbijo za bolnika, morajo biti pri ravnanju z uporabljenimi iglami nadvse pazljive, da zmanjšajo tveganje za vbode z iglami in prenos okužb.
Injecting your dose Make sure that you receive your full dose by using the right injection technique.
Prepričajte se, da injicirate celoten odmerek z uporabo pravilnega postopka injiciranja.
Insulins and analogues for injection, long-acting: ATC code: A10AE05.
Oznaka ATC: A10AE05.
During use or when carried as a spare: Levemir Penfill that is being used or carried as a spare should not be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo Levemir Penfill, ki ga uporabljate ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
Dispose of it carefully and put the pen cap back on your FlexPen.
Pazljivo jo zavrzite in na injekcijski peresnik FlexPen znova namestite njegov pokrovček.
What Levemir contains
Kaj vsebuje zdravilo Levemir
► If you are allergic to insulin detemir or any of the other ingredients in this medicine, see section
Ne uporabljajte zdravila Levemir: ► če ste alergični na insulin detemir ali katero koli drugo sestavino tega zdravila (glejte poglavje
• The other ingredients are glycerol, phenol, metacresol, zinc acetate, disodium phosphate dihydrate, sodium chloride, hydrochloric acid, sodium hydroxide and water for injections.
• Pomožne snovi so glicerol, fenol, metakrezol, cinkov acetat, natrijev hidrogenfosfat dihidrat, natrijev klorid, klorovodikova kislina, natrijev hidroksid in voda za injekcije.
In the trial comparing Levemir vs. insulin degludec, the rate of hyperglycaemic episodes with ketosis was significantly higher for Levemir, 1.09 and 0.68 episodes per patient-year of exposure, respectively.
V preskušanju, v katerem so zdravilo Levemir primerjali z insulinom degludek, je bil delež hiperglikemičnih epizod s ketozo pri uporabi zdravila Levemir pomembno večji (1,09 v primerjavi z 0,68 epizod na bolnik-leto izpostavljenosti).
No pharmacokinetic or pharmacodynamic interactions were observed between liraglutide and Levemir when administering a single dose of Levemir 0.5 units/kg with liraglutide 1.8 mg at steady state in patients with type 2 diabetes.
Med liraglutidom in zdravilom Levemir niso opazili medsebojnih farmakokinetičnih ali farmakodinamskih interakcij, če je bilo zdravilo Levemir pri osebah s sladkorno boleznijo tipa 2 uporabljeno v enkratnem odmerku 0,5 enot/kg z 1,8 mg liraglutida v stanju dinamičnega ravnovesja.
Glycaemic control (HbA1c) with Levemir was comparable to NPH insulin, with a lower risk of nocturnal hypoglycaemia and no associated weight gain.
Glikemično uravnavanje (HbA1c) z zdravilom Levemir je bilo mogoče primerjati z insulinom NPH, pri čemer je tveganje za nočno hipoglikemijo nižje ter brez hkratnega pridobivanja na telesni masi.
Activity profiles of Levemir in patients with type 1 diabetes
Slika 1: Potek delovanja zdravila Levemir pri bolnikih s sladkorno boleznijo tipa 1
Within-patient variation in absorption is lower for Levemir than for other basal insulin preparations.
Razlike v absorpciji med bolniki so pri zdravljenju z zdravilom Levemir manjše kot pri drugih zdravilih, ki se uporabljajo kot bazalni insulin.
The trials demonstrated that glycaemic control (HbA1c) with Levemir is comparable to NPH insulin and insulin degludec when given as basal-bolus therapy, using a noninferiority margin of 0.4%.
Vsa preskušanja so pokazala, da je urejenost glikemije (HbA1c) z zdravilom Levemir primerljiva tisti z insulinom NPH in insulinom degludek, če je uporabljen v bazalno-bolusnem zdravljenju; uporabljena meja neinferiornosti je bila 0,4 %.
Studies in patients with type 2 diabetes treated with basal insulin in combination with oral antidiabetic medicinal products demonstrated that glycaemic control (HbA1c) with Levemir is comparable to NPH insulin and insulin glargine and associated with less weight gain, see Table 2 below.
Študije pri bolnikih s sladkorno boleznijo tipa 2, zdravljenih z bazalnim insulinom v kombinaciji s peroralnimi antidiabetiki so pokazale, da je urejenost glikemije (HbA1c) ob zdravilu Levemir primerljiva z urejenostjo pri insulinu NPH in insulinu glargin, obenem je manj povečanja telesne mase (glejte preglednico 2, spodaj).
The efficacy and safety of Levemir has been studied for up to 12 months, in three randomised controlled clinical trials in adolescents and children (n=1045 in total); the trials included in total 167 children aged 1-5 years.
Učinkovitost in varnost zdravila Levemir so do 12 mesecev preučevali v treh randomiziranih, kontroliranih kliničnih preskušanjih pri mladostnikih in otrocih (skupni n = 1045).
Levemir can be used with meal-related rapid acting insulin medicines.
Zdravilo Levemir se lahko uporablja skupaj s hitrodelujočimi insulini, ki se jih uporablja ob obroku.
In long-term trials in patients with type 1 diabetes receiving a basal-bolus insulin therapy, fasting plasma glucose was improved with Levemir compared with NPH insulin.
V dolgoročnih preskušanjih pri bolnikih s sladkorno boleznijo tipa 1, ki so prejemali bazalno-bolusno zdravljenje z insulinom, se je stanje plazemske glukoze na tešče pri zdravilu Levemir izboljšalo v primerjavi z insulinom NPH.
For patients who require twice daily dosing to optimise blood glucose control, the evening dose can be administered in the evening or at bedtime.
Bolnikom, ki zaradi boljšega uravnavanja glukoze v krvi potrebujejo odmerjanje dvakrat dnevno, je mogoče večerni odmerek aplicirati zvečer ali pred spanjem.
These reactions include pain, redness, hives, inflammation, bruising, swelling and itching at the injection site.
Med takšnimi reakcijami so bolečina, pordelost, koprivnica, vnetje, podplutbe, oteklina in srbenje na mestu injiciranja.
What Levemir looks like and contents of the pack Levemir is presented as a solution for injection.
Izgled zdravila Levemir in vsebina pakiranja Zdravilo Levemir je na voljo v obliki raztopine za injiciranje.
What Levemir looks like and contents of the pack
Izgled zdravila Levemir in vsebina pakiranja
NPH insulin Insulin glargine
Insulin NPH Insulin glargin
You cannot set a dose larger than the number of units remaining in the cartridge.
Nastaviti ne morete odmerka, ki bi bil večji od števila preostalih enot v vložku.
Within-subject variability of the time action profile of Levemir and NPH insulin Pharmacodynamic Endpoint
Spremenljivost časovnega poteka delovanja zdravila Levemir in insulina NPH
Painful neuropathy (pain due to nerve damage): If your blood sugar level improves very fast, you may get nerve related pain, this is called acute painful neuropathy and is usually transient.
Boleča nevropatija (bolečina zaradi okvare živca): če se koncentracija krvnega sladkorja izboljša zelo hitro, lahko doživite z živci povezane bolečine.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction and development.
Neklinični podatki na podlagi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih, genotoksičnosti in vpliva na sposobnost razmnoževanja in razvoja ne kažejo posebnega tveganja za ljudi.
Levemir should not be added to infusion fluids.
Zdravila Levemir se ne sme dodajati infuzijskim tekočinam.
Mean change in HbA1c from baseline (%)
Povprečna sprememba HbA1c od izhodišča (%)
The absolute bioavailability of insulin detemir when administered subcutaneous is approximately
Absolutna biološka uporabnost insulina detemir znaša pri subkutani aplikaciji približno 60 %.
If one SMPG measurement 3.1-4.0 mmol/l (56-72 mg/dl)
V primeru enkratne vrednosti SIGP 3,1-4,0 mmol/l (56-72 mg/dl)
► If you drink alcohol, your need for insulin may change as your blood sugar level may either rise or fall.
Zdravilo Levemir skupaj z alkoholom ► Če pijete alkohol, se vam potreba po insulinu lahko spremeni, kajti koncentracija krvnega sladkorja se vam lahko poveča ali zmanjša.
1 ml of the solution contains 100 units insulin detemir* (equivalent to 14.2 mg).
1 ml raztopine vsebuje 100 enot insulina detemir* (kar ustreza 14,2 mg).
Allergic reactions, potentially allergic reactions, urticaria, rash, eruptions Allergic reactions, potentially allergic reactions, urticaria, rash and eruptions are uncommon when Levemir is used in basal-bolus regimen.
Alergijske reakcije, potencialne alergijske reakcije, urtikarija, izpuščaj, erupcije Med uporabo zdravila Levemir v bazalno-bolusni shemi so alergijske reakcije, potencialne alergijske reakcije, urtikarija, izpuščaj in erupcije občasni neželeni učinki.
There was no clinically relevant difference in pharmacokinetics of Levemir between elderly and young patients.
Klinično pomembne razlike v farmakokinetiki zdravila Levemir med starejšimi in mlajšimi bolniki niso bile ugotovljene.
Levemir is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Zdravilo Levemir je namenjeno zdravljenju sladkorne bolezni pri odraslih, mladostnikih in otrocih, starih 1 leto in več.
LIST OF EXCIPIENTS glycerol, phenol, metacresol, zinc acetate, disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide for pH adjustment and water for injections
SEZNAM POMOŽNIH SNOVI glicerol, fenol, metakrezol, cinkov acetat, natrijev hidrogenfosfat dihidrat, natrijev klorid, klorovodikovo kislino/natrijev hidroksid za uravnavanje pH in vodo za injekcije.
Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Levemir and other insulin products.
Preprečevanje nenamerne zamenjave zdravil/napak pri zdravljenju Bolnikom je treba naročiti, da pred vsakim injiciranjem vedno preverijo nalepko na vložku/injekcijskem peresniku in tako preprečijo nenamerno zamenjavo zdravila Levemir in drugih insulinskih zdravil.
Levemir is for injection under the skin (subcutaneously).
Zdravilo Levemir je namenjeno injiciranju pod kožo (subkutani uporabi).
Common - Injection site reactions
Pogosto - reakcije na mestu injiciranja
Needles, cartridges and pre-filled pens must not be shared.
Igel, vložkov in napolnjenih injekcijskih peresnikov si ne delite z drugimi.
During use or when carried as a spare: Levemir InnoLet that is being used or carried as a spare should not be kept in the refrigerator.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo Levemir InnoLet, ki ga uporabljate ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
Levemir Penfill is designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist needles.
Zdravilo Levemir Penfill je namenjen za uporabo z aplikacijskimi sistemi Novo Nordisk in iglami NovoFine ali NovoTwist.
An open-label randomised clinical trial in patients with type 2 diabetes not reaching target with oral antidiabetic medicinal products was conducted.
Pri bolnikih s sladkorno boleznijo tipa 2, ki s peroralnimi antidiabetiki niso dosegli cilja, je bilo izvedeno odprto, randomizirano klinično preskušanje.
Levemir is a long-acting insulin analogue used as a basal insulin.
Zdravilo Levemir je dolgodelujoči insulinski analog, ki se uporablja kot bazalni insulin.
+3 units
+ 3 enote
Dose proportionality in serum concentrations (maximum concentration, extent of absorption) is observed after subcutaneous administration in the therapeutic dose range.
Po subkutani aplikaciji v terapevtskem območju so koncentracije v serumu (največja vsebnost, obseg absorpcije) sorazmerne odmerku.
0-26 weeks 0.286 0-52 weeks 0.228
0-26 tednov 0,286 0-52 tednov 0,228
(5%) for Levemir and 11 (7%) for NPH with 3 (4%) major malformations for Levemir and 3 (2%) for NPH.
NPH pa 11 (pogostnost 7 %), pri čemer so bile pri zdravilu Levemir hujše hibe 3 (4 %) in pri insulinu NPH 3 (2 %).
• Dial 2 units by turning the dose selector clockwise.
• Nastavite 2 enoti tako, da izbirnik odmerka zasučete v smeri urnega kazalca.
0-26 weeks 43.1 0-52 weeks 51.9
0-26 tednov 43,1 0-52 tednov 51,9
H. Press the dose button with your thumb until the dose counter returns to 0.
H. S palcem pritisnite potisni gumb, dokler se števec odmerka ne vrne na 0.
Breast-feeding women may require adjustments in insulin dose and diet.
Doječim materam je morda treba prilagoditi odmerke in prehrano.
In an open-label randomised controlled clinical trial pregnant women with type 1 diabetes (n=310) were treated in a basal-bolus treatment regimen with Levemir (n=152) or NPH insulin (n=158) as basal insulin, both in combination with NovoRapid.
V odprtem, randomiziranem, kontroliranem kliničnem preskušanju so nosečnice s sladkorno boleznijo tipa 1 (n = 310) zdravili z bazalno-bolusno shemo, v kateri je bil bazalni insulin bodisi zdravilo Levemir (n = 152) bodisi insulin NPH (n = 158), oba v kombinaciji z zdravilom NovoRapid.
1 ml solution contains 100 units insulin detemir (equivalent to 14.2 mg).
1 ml raztopine vsebuje 100 enot insulina detemir (kar ustreza 14,2 mg),
The safety and efficacy of Levemir in children below the age of 1 year have not been established.
Varnost in učinkovitost zdravila Levemir pri otrocih, mlajših od 1 leta, nista bili dokazani.
Based on post-marketing sources and clinical trials, the frequency, type and severity of adverse reactions observed in the paediatric population do not indicate any differences to the broader experience in the general diabetes population.
Pogostnost, vrsta in izrazitost neželenih učinkov, opaženih v pediatrični populaciji na podlagi podatkov po prihodu zdravila na trg in kliničnih preskušanj, ne kažejo razlik v primerjavi s širšimi izkušnjami v splošni populaciji sladkornih bolnikov.
Change in body weight from baseline (kg)
Sprememba telesne mase od izhodišča (kg)
See table 3.
Glejte preglednico 3.
Checking the insulin flow Make sure that you receive your full dose by always checking the insulin flow before you select and inject your dose.
Prepričajte se, da boste injicirali celoten odmerek tako, da preden izberete in injicirate želeni odmerek vedno preverite pretok insulina.
During use or when carried as a spare: You can carry your Levemir FlexPen with you and keep it at a temperature below 30°C or in a refrigerator (2°C to 8°C) for up to 6 weeks.
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravilo Levemir FlexTouch lahko nosite s seboj in shranjujete pri temperaturi do 30 °C ali v hladilniku (2 °C - 8 °C) do 6 tednov.
Each cartridge contains 300 units of insulin detemir in 3 ml solution for injection.
En vložek vsebuje 300 enot insulina detemir v 3 ml raztopine za injiciranje.
Levemir + liraglutide + metformin n=160
metformin n = 160
In children and adolescents, glucose monitoring should be intensified and the Levemir dose adjusted on an individual basis.
Pri otrocih in mladostnikih je treba koncentracijo glukoze v krvi spremljati pozorneje ter odmerek zdravila Levemir individualno prilagoditi.
In patients with renal or hepatic impairment, glucose monitoring should be intensified and the Levemir dose adjusted on an individual basis.
Pri bolnikih z ledvično ali jetrno okvaro je treba koncentracijo glukoze v krvi spremljati pozorneje ter odmerek zdravila Levemir prilagoditi posamezniku.
Levemir is presented as a solution for injection.
Zdravilo Levemir je na voljo v obliki raztopine za injiciranje.
Levemir was studied in an open-label randomised controlled clinical trial, pregnant women with type 1 diabetes (n=310) were treated in a basal-bolus treatment regimen with Levemir (n=152) or NPH insulin (n=158) as basal insulin, both in combination with NovoRapid (see section 4.6).
V odprtem, randomiziranem, kontroliranem kliničnem preskušanju so nosečnice s sladkorno boleznijo tipa 1 (n = 310) zdravili z bazalno-bolusno shemo, v kateri je bil bazalni insulin bodisi zdravilo Levemir (n = 152) bodisi insulin NPH (n = 158), oba v kombinaciji z zdravilom NovoRapid (glejte poglavje 4.6).
InnoLet is designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. As a precautionary measure, always carry a spare insulin delivery device in case your InnoLet in use is lost or damaged.
Injekcijski peresnik InnoLet je namenjen za uporabo z iglami NovoFine ali NovoTwist za enkratno uporabo, dolgimi do 8 mm. Vedno nosite s seboj rezervni sistem za injiciranje insulina, če bi se zgodilo, da injekcijski peresnik InnoLet, ki ga uporabljate, izgubite ali se poškoduje.
If you have taken any of the medicines listed here, tell your doctor, nurse or pharmacist.
Če ste uporabili katero koli zgoraj navedeno zdravilo, povejte to svojemu zdravniku, medicinski sestri ali farmacevtu.
Levemir can be used in adolescents and children aged 1 year and above.
Uporaba pri otrocih in mladostnikih Zdravilo Levemir se lahko uporablja pri mladostnikih in otrocih, starih 1 leto in več.